| $350M | ||
| $172M | ||
| $127M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream. This innovative platform has shown impressive results, boosting the bioavailability of compounds such as cannabinoids and nicotine by 5 to 10 times, and in some cannabinoid applications, by as much as 27 times, when compared to standard formulations. DehydraTECH also drastically cuts the time of onset from hours to mere minutes and effectively neutralizes unpleasant tastes. Beyond its established uses, the technology is currently under evaluation for its potential application with orally administered antiviral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and various other compounds. A notable feature of DehydraTECH is its capacity to facilitate the passage of drugs across the blood-brain barrier. The company operates a licensed internal research facility and holds a substantial intellectual property portfolio, comprising 23 granted patents and roughly 50 pending patent applications globally. Founded in 2004, Lexaria Bioscience Corp. is headquartered in Kelowna, Canada.
Over the last 12 months, insiders at Lexaria Bioscience Corp. have bought $0 and sold $0 worth of Lexaria Bioscience Corp. stock.
On average, over the past 5 years, insiders at Lexaria Bioscience Corp. have bought $85,134 and sold $10,268 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 11,900 shares for transaction amount of $10,866 was made by BUNKA CHRISTOPHER (director) on 2025‑07‑30.
| 2025-07-30 | BUNKA CHRISTOPHER | director | 11,900 0.0607% | $0.91 | $10,866 | -14.57% | ||
| 2025-07-29 | BUNKA CHRISTOPHER | director | 15,600 0.0827% | $0.92 | $14,375 | -12.07% | ||
| 2025-07-29 | CHRISTOPHER RICHARD | Chief Executive Officer | 15,000 0.0784% | $0.91 | $13,641 | -12.07% | ||
| 2025-07-29 | McKechnie William Edward | director | 5,000 0.0261% | $0.91 | $4,532 | -12.07% | ||
| 2025-07-29 | DOCHERTY JOHN MARTIN | President & CSO | 5,376 0.0287% | $0.93 | $4,989 | -12.07% | ||
| 2025-07-29 | Carle Vanessa | Secretary | 750 0.0039% | $0.91 | $683 | -12.07% | ||
| 2024-12-03 | CHRISTOPHER RICHARD | Chief Executive Officer | 27,172 0.1442% | $2.47 | $67,175 | -60.00% | ||
| 2024-12-02 | CHRISTOPHER RICHARD | Chief Executive Officer | 22,828 0.1328% | $2.24 | $51,217 | -51.79% | ||
| 2024-08-12 | TURKEL CATHERINE C. | director | 1,600 0.0097% | $3.13 | $5,008 | -46.64% | ||
| 2024-07-31 | Sale | Carle Vanessa | Secretary | 2,567 0.0177% | $4.00 | $10,268 | -55.87% | |
| 2023-02-09 | TURKEL CATHERINE C. | director | 1,500 0.0253% | $2.84 | $4,267 | -55.28% | ||
| 2022-10-14 | Downey Gregory | Chief Financial Officer | 121 0.002% | $2.09 | $253 | +1.66% | ||
| 2022-10-13 | BUNKA CHRISTOPHER | Chief Executive Officer | 16,600 0.275% | $2.10 | $34,860 | +0.47% | ||
| 2022-10-12 | BUNKA CHRISTOPHER | Chief Executive Officer | 21,900 0.3658% | $1.99 | $43,537 | +7.00% | ||
| 2018-05-30 | Sale | McKechnie William Edward | 47,900 0.0843% | $1.90 | $91,011 |
| BUNKA CHRISTOPHER | director | 281912 17.0598% | $3.99M | 4 | 0 | <0.0001% |
| CHRISTOPHER RICHARD | Chief Executive Officer | 65000 3.9334% | $919,750.00 | 3 | 0 | <0.0001% |
| McKechnie William Edward | director | 18191 1.1008% | $257,402.65 | 1 | 1 | <0.0001% |
| DOCHERTY JOHN MARTIN | President & CSO | 5376 0.3253% | $76,070.40 | 1 | 0 | <0.0001% |
| TURKEL CATHERINE C. | director | 3100 0.1876% | $43,865.00 | 2 | 0 | <0.0001% |
| Downey Gregory | Chief Financial Officer | 1954 0.1182% | $27,649.10 | 1 | 0 | |
| Carle Vanessa | Secretary | 750 0.0454% | $10,612.50 | 1 | 1 | <0.0001% |
$6,204,522 | 45 | 1.91% | $28.45M | |
$30,257,839 | 29 | -15.72% | $23.91M | |
$241,165 | 22 | -16.72% | $32.32M | |
$555,628 | 21 | 43.52% | $20.2M | |
$114,619,342 | 20 | -7.41% | $19.67M | |
$352,389 | 18 | 9.66% | $33.23M | |
$742,412 | 14 | -50.36% | $19.38M | |
$1,246,170 | 12 | 65.67% | $20.72M | |
$365,792 | 12 | -15.77% | $18.94M | |
Lexaria Bioscience Corp. (LEXX) | $176,752 | 10 | -28.86% | $23.38M |
$4,176,565 | 9 | 18.77% | $22.6M | |
$8,971,546 | 8 | 6.18% | $19.9M | |
$654,995 | 7 | -60.00% | $20.68M | |
$114,586 | 6 | -12.52% | $25.14M | |
$1,124,966 | 4 | 0.87% | $18.96M | |
$1,499,988 | 3 | 0.92% | $35.41M | |
$5,512,500 | 1 | -7.91% | $28.25M | |
$35,811 | 1 | -10.94% | $23.7M | |
$150,000 | 1 | 5.48% | $24.31M |
| Increased Positions | 9 | +34.62% | 479,117 | +27.9% |
| Decreased Positions | 8 | -30.77% | 495,237 | -28.84% |
| New Positions | 2 | New | 203 | New |
| Sold Out Positions | 6 | Sold Out | 485,361 | Sold Out |
| Total Postitions | 27 | +3.85% | 2M | -0.94% |
| Invenomic Capital Management Lp | $312.00 | 1.91% | 477,201 | -24,267 | -4.84% | 2025-09-30 |
| Murchinson Ltd. | $274.00 | 1.68% | 419,590 | +419,590 | New | 2025-09-30 |
| Vanguard Group Inc | $169.00 | 1.04% | 258,816 | +125,262 | +93.79% | 2025-09-30 |
| Geode Capital Management, Llc | $114.00 | 0.7% | 174,779 | 0 | 0% | 2025-09-30 |
| Toronto Dominion Bank | $92.00 | 0.56% | 140,013 | +6,888 | +5.17% | 2025-09-30 |
| State Street Corp | $26.00 | 0.16% | 39,301 | 0 | 0% | 2025-09-30 |
| Wealth Enhancement Advisory Services, Llc | $23.00 | 0.14% | 35,776 | +5,000 | +16.25% | 2025-09-30 |
| Byrne Asset Management Llc | $20.00 | 0.13% | 31,320 | -2,889 | -8.45% | 2025-09-30 |
| Virtu Financial Llc | $19.00 | 0.12% | 29,360 | +29,360 | New | 2025-09-30 |
| Blackrock, Inc. | $18.00 | 0.11% | 27,445 | 0 | 0% | 2025-09-30 |